Prescriber beware: Report of adverse effect of sodium-glucose cotransporter 2 inhibitor use in a patient with contraindication

American Journal of Emergency Medicine

Volumn 33, Issue 4, 2015, Pages 604.e3-604.e4

  St Hilaire, Reginald ^a   Costello, Heather ^b  

^a UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^b NORTHSHORE UNIVERSITY HEALTHSYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BICARBONATE; GLUCOSE; INSULIN; LORAZEPAM; ONDANSETRON; POTASSIUM; SODIUM CHLORIDE; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR;

ADULT; ARTICLE; BICARBONATE BLOOD LEVEL; CASE REPORT; DIABETIC KETOACIDOSIS; DRUG CONTRAINDICATION; DRUG MISUSE; EMERGENCY PHYSICIAN; EMERGENCY WARD; GLUCOSE BLOOD LEVEL; GLUCOSE URINE LEVEL; HUMAN; HYPERKALEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN PUMP; INSULIN TREATMENT; INTENSIVE CARE UNIT; KETONURIA; LABORATORY TEST; MALAISE; MALE; NAUSEA; OFF LABEL DRUG USE; PHYSICAL EXAMINATION; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; RESTLESSNESS; RESUSCITATION; SERUM OSMOLARITY; URINALYSIS; VOMITING;

EID: 84928140044     PISSN: 07356757     EISSN: 15328171     Source Type: Journal    
DOI: 10.1016/j.ajem.2014.09.039     Document Type: Article

References (6)

1. R.K. Cydulka, and G.E. Maloney Jr. Diabetes mellitus and disorders of glucose homeostasis J.A. Marx, R.S. Hockberger, R.M. Walls, Rosen's emergency medicine: concepts and clinical practice 7th ed. 2010 Mosby/Elsevier Philadelphia, PA 1633 1649
2. http://www.fda.gov/downloads/Drugs/DrugSafety/UCM346637.pdf
3. http://www.invokanahcp.com/mechanism-of-action
4. S.R. Talor, and K.B. Harris The clinical efficacy and safety of sodium glucose cotransporter-2 inhibitors in adults with type 2 diabetes mellitus Pharmacotherapy 33 9 2013 984 999
5. S. Elkinson, and L.J. Scott Canagliflozin: first global approval Drugs 73 2013 979 988
6. W.T. Cefalu, L.A. Leiter, K.H. Yoon, P. Arias, L. Nikasen, and J. Xie Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial Lancet 382 2013 941 950